Phastar, a contract research organization (CRO), has appointed Billy Amzal as Head of Strategic Consulting.

Amzal is a statistician, public health scientist, and entrepreneur with more than 25 years of experience across biotech and pharmaceutical industries, health agencies, and consulting. He brings deep expertise in innovative yet regulatory-grade statistical methodologies, including optimal and adaptive trial designs, model-based meta-analysis (MBMA), Bayesian statistics, real-world evidence, and predictive modelling.

Graham Clark, CEO of Phastar, said: “We are delighted to welcome Billy to Phastar. Throughout his career, he has focused on turning methodological innovations into real-world value—connecting science, data, and strategy to drive better outcomes. His expertise further strengthens our team of scientific and technical specialists, enhancing our ability to support pharmaceutical and biotech clients in accelerating development and bringing new therapies to market. Billy brings an ecosystem-wide perspective that will help our teams unlock even greater value for clients through high-quality, innovative, and insight-driven approaches.”

Experience

Throughout his career, Amzal has supported over 100 regulatory and pricing/reimbursement submissions with advanced, decision-shaping analytics. He is co-chair of the Statistics SIG at ISPOR, an Evaluation Committee member for the EU Commission on biomedical research funding and a statistical expert to health agencies including the World Health Organization (WHO).

Prior to joining Phastar, Amzal served as Senior Vice President at Certara and was previously CEO of Quinten Health, an AI-driven health analytics company, with whom he will continue to collaborate on strategic initiatives in his new role at Phastar.

Speaking about his motivation for joining Phastar, Amzal remarked: “It’s rare to find an organization of this scale with such a deep bench of highly qualified, innovation-driven, and client-focused data scientists. The opportunity to join a company that is not only delivering excellence in statistical and data management services but also pushing the boundaries of how data can accelerate and enhance drug development was incredibly compelling.”